Skip to main content

A Study of bbT369 in Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma (NHL)

Terminated · Phase 1 · NCT05169489

Conditions: Diffuse Large B Cell Lymphoma (DLBCL)

At a glance

Research payments reported, 2025
$513,063
U.S. investigators named
3
Sites paid
6
Planned or actual enrollment
15

About the trial

Sponsor
Regeneron Pharmaceuticals
Tested
bbT369 (biological)
Dates
Started 2022-01-24; completion 2025-09-19
Results posted
Not yet

This non-randomized, open label, multi-site, first-in-human, Phase 1/2 study CRC-403 will evaluate the safety and efficacy of bbT369 in subjects with relapsed and/or refractory B cell non-Hodgkin's lymphoma (NHL). A long-term follow-up (LTF-01 \[NCT06798298\]) is planned, in which subjects who received bbT369 will be followed for up to 15 years after drug product infusion to evaluate for safety and continued efficacy.

From ClinicalTrials.gov, last updated 2025-10-21. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Regeneron Pharmaceuticals, Inc. reported $513,063 in research payments for this study in 2025 (48 payments).

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

  • Board of Trustees of the Leland Stanford Junior University $214,116
  • Tennessee Oncology PLLC $87,016
  • Moffitt Cancer Center $82,004
  • The Board of Trustees of the Leland Stanford Jr University $60,223
  • H Lee Moffitt Cancer Center and Research Institute Inc $51,192
  • Sarah Cannon $18,512

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.